This meeting will focus on ground-breaking advances in genomics for target choice, in vitro technologies, novel modalities, risk mitigation, data analysis, AI/ML, digital health, and how they could radically increase the discovery of disease relevant biological targets and the development of new drugs.
Both audiences, face-to-face and virtual, will experience presentations from our esteemed panel of speakers, participate in live Q&A and panel discussion sessions, take advantage of networking opportunities, poster sessions, vendor exhibitions and on-demand materials.
Participants from industry, academia and government interested in challenging the existing approaches to target selection and translation are encouraged to attend, and set the agenda for the next era of drug discovery.
Keynote speakers:
- Professor Sir Munir Pirmohamed, NHS Chair of Pharmacogenetics, University of Liverpool, Director of the Wolfson Centre for Personalised Medicine and MRC Centre for Drug Safety Sciences, Commissioner on Human Medicines (CHM) | UK.
- Dr. Melanie Lee CBE, CEO, Think 10, Formerly CEO, LifeArc | UK
Hinxton Hall Conference Centre, Wellcome Genome Campus, Hinxton, UK. CB10 1RQ or ONLINE
Early bird discount ends: 26 February 2024. Student and academic discounts available.
Abstracts for consideration for poster presentations can be submitted during registration.
Sponsors: EMBL-EBI, GSK, AstraZeneca
Supported by: ELRIG, SMR
